Whitehawk Therapeutics, Inc. (WHWK) Form 10-Q — Aug 6, 2026
Whitehawk Therapeutics reported a Q2 2026 net loss of $16.6 million, or $0.20 per share, on zero revenue, as the company remains pre-commercial following the March 2025 divestiture of its FYARRO business to KAKEN for $102.4 million. R&D expense of $12.9 million drove the quarter's $18.1 million operating loss. The company ended the quarter with $190.0 million in cash, cash equivalents and short-term investments, bolstered by $81.8 million in net proceeds from its May 2026 PIPE financing (shares priced at $3.92). Management believes this funds planned operations into the second half of 2028, though shares outstanding rose roughly 21% year-to-date to 57.0 million.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 193994000
- Cash Position
- 85234000
- Shares Outstanding
- 57009010
- Cash runway
- into the second half of 2028
- H1 2025 net income
- 20401000
- Q2 2026 rd expense
- 12893000
- Accumulated deficit
- 392084000
- Atm capacity unused
- 75000000
- Q2 2026 sga expense
- 5216000
- Short term investments
- 104748000
- Fyarro divestiture gain
- 87400000
- May 2026 pipe net proceeds
- 81800000
- Fyarro divestiture proceeds
- 102400000
- Shares outstanding dec 31 2025
- 47145719
- Cash cash equivalents and short term investments
- 190000000
Price after filing
Close on the filing date to close N calendar days later (from $4.14). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.